Search

Your search keyword '"Allergan PLC -- Product development"' showing total 12 results
Start Over Descriptor "Allergan PLC -- Product development" Publisher plus media solutions
12 results on '"Allergan PLC -- Product development"'

1. Allergan and Editas Medicine Announce Dosing of First Patient in Landmark Phase 1|2 Clinical Trial of CRISPR Medicine AGN-151587 (EDIT-101) for the Treatment of LCA10

Subjects
Allergan PLC -- Product development, Clinical trials, Pharmaceutical industry -- Product development, Blindness, Genes, Genetic disorders, Genomics, Health, General interest, News, opinion and commentary, Oregon Health & Science University
Abstract

DUBLIN: Editas Medicine, Inc. has issued the following press release: Allergan plc (NYSE: AGN), a leading global pharmaceutical company, and Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, [...]

Published
2020

2. Alzheimer's Disease Global Clinical Trials Review, H2, 2019 - Pfizer Inc, Eisai Co Ltd, Allergan Plc & The Lundbeck Foundation

Subjects
Allergan PLC -- Product development, Pfizer Inc. -- Product development, Eisai Company Ltd. -- Product development, Clinical trials, Anti-Alzheimer's disease agents -- Product development, Pharmaceutical industry -- Product development, Alzheimer's disease, Diseases, General interest, News, opinion and commentary
Abstract

DUBLIN: Research and Markets has issued the following news release: The 'Alzheimer's Disease Global Clinical Trials Review, H2, 2019' clinical trials has been added to ResearchAndMarkets.com's offering. Summary The clinical [...]

Published
2020

3. Global Wrinkles Clinical Trials Review, H2 2019 - Allergan Plc, Bausch Health Companies Inc, L'Oreal SA & Huons Global Co Ltd

Subjects
Allergan PLC -- Product development, L'Oreal S.A. -- Product development, Clinical trials, Pharmaceutical industry -- Product development, Cosmetics industry -- Product development, Diseases, General interest, News, opinion and commentary
Abstract

DUBLIN: Research and Markets has issued the following news release: The 'Wrinkles Global Clinical Trials Review, H2, 2019' clinical trials has been added to ResearchAndMarkets.com's offering. Wrinkles Global Clinical Trials [...]

Published
2020

4. Allergan Announces Positive Phase 3 ACHIEVE I Trial Results for Ubrogepant Published in The New England Journal of Medicine

Subjects
Allergan PLC -- Product development, Clinical trials, Pharmaceutical industry -- Product development, Migraine -- Care and treatment, Periodicals, General interest, News, opinion and commentary
Abstract

DUBLIN: Allergan plc has issued the following press release: Allergan plc (NYSE: AGN) today announced that positive results from ACHIEVE I (UBR-MD-01), a robust Phase 3 clinical trial evaluating the [...]

Published
2019

5. Allergan Announces Positive Phase 3 ACHIEVE II Trial Results for Ubrogepant Published in The Journal of the American Medical Association

Subjects
Allergan PLC -- Product development, Clinical trials, Pharmaceutical industry -- Product development, Migraine -- Care and treatment, General interest, News, opinion and commentary
Abstract

DUBLIN: Allergan plc has issued the following press release: Allergan plc (NYSE: AGN) today announced that positive results from ACHIEVE II (UBR-MD-02), a pivotal Phase 3 clinical trial evaluating the [...]

Published
2019

6. Allergan and Molecular Partners Present Late-Breaking Data from Phase 3 Studies of Investigational Abicipar pegol in Neovascular Wet Age-Related Macular Degeneration

Subjects
Allergan PLC -- Product development, Clinical trials -- Physiological aspects, Macular degeneration -- Physiological aspects, Ranibizumab -- Physiological aspects, Medical research -- Physiological aspects, Pharmaceutical industry -- Product development -- Physiological aspects, Ophthalmology, General interest, News, opinion and commentary
Abstract

DUBLIN: Allergan plc has issued the following press release: Allergan plc, (NYSE: AGN), a leading global pharmaceutical company with a more than 70-year heritage in ophthalmology and Molecular Partners (SIX: [...]

Published
2019

7. Allergan and Editas Medicine Initiate the Brilliance Phase 1|2 Clinical Trial of AGN-151587 (EDIT-101) for the Treatment of LCA10

Subjects
Allergan PLC -- Product development, Clinical trials, Pharmaceutical industry -- Product development, Blindness, Genetic research, Genes, Genetic disorders, Genomics, General interest, News, opinion and commentary
Abstract

Massachusetts: Editas Medicine, Inc. has issued the following press release: Allergan plc (NYSE: AGN), a leading global pharmaceutical company, and Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, [...]

Published
2019

8. Medicines360 and Allergan Present Six-Year Clinical Data from Largest Ongoing Phase 3 Study of an Intrauterine System in the U.S

Subjects
Allergan PLC -- Product development, Pharmaceutical industry -- Product development, Clinical trials, Medical research, Contraceptives -- Product development, Levonorgestrel, Medical societies, Obstetricians, Women's health, Contraceptive drug implants, Health, Physicians, General interest, News, opinion and commentary, American College of Obstetricians and Gynecologists
Abstract

SAN FRANCISCO and DUBLIN: Medicines360 has issued the following news release: Medicines360, a nonprofit women's health pharmaceutical company with a mission of expanding access to quality medicines, and Allergan plc [...]

Published
2019

9. Allergan Announces Positive 3-Month Topline Results from Second Phase 3 Study of Bimatoprost SR (Sustained-Release) Implant for Lowering Intraocular Pressure (IOP) in Patients with Open-Angle Glaucoma or Ocular Hypertension

Subjects
Allergan PLC -- Product development, Pharmaceutical industry -- Product development, General interest, News, opinion and commentary
Abstract

DUBLIN: Allergan plc has issued the following news release:Allergan plc, (NYSE: AGN), a leading global pharmaceutical company, today announced positive 3-month topline results from the second pivotal clinical trial of [...]

Published
2019

10. Amgen And Allergan Announce Top-Line Results From Phase 3 Study Evaluating ABP 980 Compared With Trastuzumab In Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer

Subjects
Amgen Inc. -- Product development, Allergan PLC -- Product development, Biotechnology industries -- Product development, Epidermal growth factors, Pharmaceutical industry -- Product development, Breast cancer -- Care and treatment, Trastuzumab -- Product development, General interest, News, opinion and commentary
Abstract

California: Amgen Inc.has issued the following news release Amgen (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) today announced results from a Phase 3 study evaluating efficacy and safety of ABP 980 compared [...]

Published
2016

11. Allergan and Richter Announce Positive Phase III Results for Ulipristal Acetate 5 and 10 mg in the Treatment of Uterine Fibroids

Subjects
Allergan PLC -- Product development, Pharmaceutical industry -- Product development, General interest, News, opinion and commentary
Abstract

Dublin:Allergan, Plc has issued the following news release:Allergan Plc (NYSE: AGN) and Gedeon Richter Plc. today announced positive results from Venus I, one of two pivotal Phase III clinical trials [...]

Published
2016

12. Ulipristal meets Phase III uterine fibroid endpoints

Subjects
Allergan PLC -- Product development, Pharmaceutical industry -- Product development, General interest, News, opinion and commentary
Abstract

San Carlos, CA: BioCentury has issued the following news release:Allergan plc (NYSE:AGN) and Gedeon Richter Ltd. (Budapest:RICHTER) said ulipristal acetate (PGL4001) met the co-primary and secondary endpoints in the Phase [...]

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results